# Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

> **NCT00455312** · PHASE2,PHASE3 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 36 (actual)

## Conditions studied

- Dyskeratosis Congenita
- Aplastic Anemia

## Interventions

- **DRUG:** Campath 1H
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Total Body Irradiation
- **PROCEDURE:** Stem Cell Transplantation
- **DRUG:** antithymocyte globulin
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT00455312
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2015-03
- **Final completion:** 2016-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00455312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00455312, "Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00455312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*